Repligen

Repligen Net Income

The Net Income of Repligen (RGEN) as of Oct 31, 2026 is 48.89 M USD. In the previous year, Net Income was -25.51 M USD — a change of -291.64% (higher).

Net Income

48.89 MUSD

YoY

-291.64%

Last updated:

In 2025, Repligen's profit amounted to 48.89 M USD, a -291.64% increase from the -25.51 M USD profit recorded in the previous year.

The Repligen Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
41.58 M USD
Jan 1, 2024
-25.51 M USD
Jan 1, 2025
48.89 M USD
Jan 1, 2026 (e)
115.22 M USD
Jan 1, 2027 (e)
148.34 M USD
Jan 1, 2028 (e)
194.62 M USD
Jan 1, 2029 (e)
251.53 M USD
Jan 1, 2030 (e)
313.53 M USD
The Repligen Net Income history
YEARNet IncomeYoY
est313.53 MUSD+24.65%
est251.53 MUSD+29.24%
est194.62 MUSD+31.20%
est148.34 MUSD+28.74%
est115.22 MUSD+135.66%
48.89 MUSD-291.64%
-25.51 MUSD-161.37%
41.58 MUSD-77.64%
185.96 MUSD+44.95%
128.29 MUSD+114.08%
59.93 MUSD+179.88%
21.41 MUSD+28.85%
16.62 MUSD-41.39%
28.35 MUSD+142.73%
11.68 MUSD+25.00%
9.35 MUSD+14.38%
8.17 MUSD-49.23%
16.09 MUSD+13.68%
14.16 MUSD-100.88%
-1.61 BUSD+3.71 M%
-43,509.00USD-98.93%
-4.06 MUSD-170.72%
5.75 MUSD-84.51%
37.11 MUSD-4,272.73%
-889,263.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Repligen Revenue

Repligen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
638.76 M USD
56.21 M USD
41.58 M USD
Jan 1, 2024
634.44 M USD
-35.11 M USD
-25.51 M USD
Jan 1, 2025
738.26 M USD
82.75 M USD
48.89 M USD
Jan 1, 2026 (e)
830.23 M USD
164.18 M USD
115.22 M USD
Jan 1, 2027 (e)
985.75 M USD
204.26 M USD
148.34 M USD
Jan 1, 2028 (e)
1.15 B USD
263.37 M USD
194.62 M USD
Jan 1, 2029 (e)
1.30 B USD
333.42 M USD
251.53 M USD
Jan 1, 2030 (e)
1.50 B USD
411.01 M USD
313.53 M USD

Repligen Margins

Repligen stock margins

The Repligen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Repligen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Repligen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
44.50 %
8.80 %
6.51 %
Jan 1, 2024
43.29 %
-5.53 %
-4.02 %
Jan 1, 2025
47.09 %
11.21 %
6.62 %
Jan 1, 2026 (e)
47.09 %
19.78 %
13.88 %
Jan 1, 2027 (e)
47.09 %
20.72 %
15.05 %
Jan 1, 2028 (e)
47.09 %
22.85 %
16.89 %
Jan 1, 2029 (e)
47.09 %
25.73 %
19.41 %
Jan 1, 2030 (e)
47.09 %
27.41 %
20.91 %

Repligen Stock analysis

What does Repligen do? Repligen Corp is an American company that was founded in 1981 and is headquartered in Waltham, Massachusetts. The company is a leading provider of products for the biopharmaceutical industry. It offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The history of Repligen Corp begins in the 1980s when the company was originally founded to produce human proteins for medical purposes. Over the years, the company expanded its business and focused on the production of purification solutions for the biopharmaceutical industry. Today, Repligen is an established company in this field and serves customers around the world. Business model: Repligen Corp is a leading provider of products and services for the biopharmaceutical industry. The company focuses on the development and manufacturing of products for the purification of proteins and antibodies. These products are used by biotech and pharmaceutical customers to improve the effectiveness and safety of their products in the clinical development process. Repligen Corp is generally able to achieve good prices for its products as they are high-quality products for a high-priced industry. The company is also interested in introducing new products to the market and expanding its customer base. Various divisions: Repligen Corp offers a wide range of innovative products and services that contribute to the acceleration and improvement of the development of biological drugs. The company is divided into various divisions, including: 1. Chromaflow: Repligen's Chromaflow products offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. These products enable customers to test and develop their products faster and more effectively. 2. Protein A Adsorbent Resin: Repligen Corp offers a Protein A Adsorbent Resin used in biotherapy. It allows for highly efficient purification of therapeutics produced using Protein A. 3. Alternating Tangential Flow (ATF) Systems: Repligen's ATF system enables continuous cell culture of proteins and antibodies. This facilitates the production of biopharmaceutical products and shortens development time. 4. Process Analytical Technology (PAT): Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. It improves process control and reduces the risk of errors and failures. 5. Filtration products: Repligen's filtration products include disposable filters and microfiltration membranes. These products are used by customers in the biopharmaceutical industry for the purification of biological products. Products: Repligen Corp offers a wide range of innovative products and services to support the development of biological drugs. Here are some of the products offered by Repligen Corp: 1. Protein A Adsorbent Resin: This product is used in biotherapy and the biopharmaceutical industry to enable highly efficient purification of therapeutics produced using Protein A. 2. Alternating Tangential Flow (ATF) Systems: This system enables continuous cell culture of proteins and antibodies. It facilitates the production of biopharmaceutical products and shortens development time. 3. Chromaflow products: They offer a wide range of purification solutions for proteins and antibodies used in the biopharmaceutical industry. 4. PAT systems: Repligen Corp's PAT system allows for accurate monitoring of the manufacturing process of biopharmaceutical products. 5. Filtration products: Repligen's filtration products include disposable filters and membranes. These products are used by customers in the biopharmaceutical industry to purify biological products. In summary, Repligen Corp is an established company that focuses on the development and production of products and services for the biopharmaceutical industry. The company offers a wide range of innovative products that contribute to the acceleration and improvement of the development of biological drugs. With its long history and established reputation as a leading provider, Repligen Corp is a significant player in the biopharmaceutical industry. Repligen is one of the most popular companies on Eulerpool.

Net Income Details

Understanding Repligen's Profit Margins

The profit margins of Repligen represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Repligen's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Repligen's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Repligen's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Repligen’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Repligen stock

Net Income of Repligen is 48.89 M USD in 2025.

Net Income of Repligen changed from -25.51 M USD to 48.89 M USD, representing a -291.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Income Repligen since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's Repligen historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Repligen

All Key Metrics — Repligen